Abvc Biopharma (ABVC) Net Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly Net Margin came in at 394.74% in Q4 2025, down 52815150.0% YoY from N/an in Q4 2024, and down 99.93% on a QoQ basis from 528546.24% in Q4 2024.
Abvc Biopharma (ABVC) Net Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has 13 years of Net Margin data on file, last reported at 394.74% in Q4 2025.
- Quarterly Net Margin fell 52815150.0% year-over-year to 394.74% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2536.71% (up 130742.0% YoY) and the FY2025 annual result came in at 26360.05%, down 2739206.0% from the prior year.
- Net Margin eased to 394.74% in Q4 2025, from 528546.24% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 528546.24% in Q4 2024 to a low of 242959.67% in Q1 2024.
- A 5-year average of 27836.13% and a median of 864.46% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin surged 28692704 bps — and 2025, when it plunged 52815150 bps.
- Tracing ABVC's Net Margin over 5 years: stood at 2015.36% in 2021, then slumped by 105 bps to 94.48% in 2022, then surged by 303692 bps to 286832.56% in 2023, then soared by 84 bps to 528546.24% in 2024, then slumped by 100 bps to 394.74% in 2025.
- The last three Net Margin figures came in at 394.74% (Q4 2025), 528546.24% (Q4 2024), and 47.93% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 394.74% |
| Dec 31, 2024 | 528,546.24% |
| Sep 30, 2024 | -47.93% |
| Jun 30, 2024 | -864.46% |
| Mar 31, 2024 | -242,959.67% |
| Dec 31, 2023 | 286,832.56% |
| Sep 30, 2023 | -20,885.90% |
| Jun 30, 2023 | -37,052.07% |
| Mar 31, 2023 | -1,421.74% |
| Dec 31, 2022 | -94.48% |
| Sep 30, 2022 | -8,764.97% |
| Jun 30, 2022 | -594.19% |
| Mar 31, 2022 | -23,364.93% |
| Dec 31, 2021 | 2,015.36% |
| Sep 30, 2021 | -1,824.75% |
| Jun 30, 2021 | -6,270.68% |
| Mar 31, 2021 | -428.84% |
| Dec 31, 2020 | -7,795.54% |
| Sep 30, 2020 | -1,597.58% |
| Jun 30, 2020 | -816.42% |